Literature DB >> 2464654

Association of tuberculosis and M. tuberculosis-specific antibody levels with HLA.

G H Bothamley1, J S Beck, G M Schreuder, J D'Amaro, R R de Vries, T Kardjito, J Ivanyi.   

Abstract

In the search for HLA-linked immune response genes that control susceptibility to tuberculosis, we performed HLA typing and measured antibody titers to well-defined Mycobacterium tuberculosis antigenic determinants in 101 patients with sputum smear-positive pulmonary tuberculosis and 64 healthy controls from Surabaya, Indonesia. HLA-DR2 and DQw1 were associated with sputum smear-positive pulmonary tuberculosis (attributable risk = 36% and 39%, respectively), while DQw3 was associated even more strongly with the control group (preventive fraction = 57%). Antibody titers to the TB71 and TB72 epitopes of the 38-kDa protein, present only on tubercle bacilli, were strongly associated with DR2 (Pcorr = .001 and .024, respectively). The association of both the disease and the antibody response to the 38-kDa antigen of M. tuberculosis with Class II HLA genes HLA-DR2 indicates that Ir-gene-mediated regulation of the immune response to this antigen may be of pathogenic significance for the development of sputum smear-positive tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464654     DOI: 10.1093/infdis/159.3.549

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

Review 1.  Factors affecting susceptibility and resistance to tuberculosis.

Authors:  P D Davies; J M Grange
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  Genetics and pulmonary medicine. 3. Genetic susceptibility to tuberculosis in human populations.

Authors:  R Bellamy
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

3.  Repertoires of antibodies to culture filtrate antigens in different mouse strains infected with Mycobacterium bovis BCG.

Authors:  K Huygen; L Ljungqvist; R ten Berg; J P Van Vooren
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

4.  Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia.

Authors:  Julio C Delgado; Eunice Y Tsai; Sok Thim; Andres Baena; Vassiliki A Boussiotis; Jean-Marc Reynes; Sun Sath; Pierre Grosjean; Edmond J Yunis; Anne E Goldfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

Review 5.  Knowledge gaining by human genetic studies on tuberculosis susceptibility.

Authors:  Hui-Qi Qu; Susan P Fisher-Hoch; Joseph B McCormick
Journal:  J Hum Genet       Date:  2010-12-23       Impact factor: 3.172

6.  Differential pattern of cytokine expression by macrophages infected in vitro with different Mycobacterium tuberculosis genotypes.

Authors:  R Chacón-Salinas; J Serafín-López; R Ramos-Payán; P Méndez-Aragón; R Hernández-Pando; D Van Soolingen; L Flores-Romo; S Estrada-Parra; I Estrada-García
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

7.  T cell response to purified filtrate antigen 85 from Mycobacterium bovis Bacilli Calmette-Guérin (BCG) in leprosy patients.

Authors:  P Launois; K Huygen; J De Bruyn; M N'Diaye; B Diouf; L Sarthouj; J Grimaud; J Millan
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

8.  Epitope-specific antibody levels demonstrate recognition of new epitopes and changes in titer but not affinity during treatment of tuberculosis.

Authors:  Graham H Bothamley
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease.

Authors:  A Elsaghier; C Prantera; C Moreno; J Ivanyi
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

10.  Heritability analysis of cytokines as intermediate phenotypes of tuberculosis.

Authors:  Catherine M Stein; David Guwatudde; Margaret Nakakeeto; Pierre Peters; Robert C Elston; Hemant K Tiwari; Roy Mugerwa; Christopher C Whalen
Journal:  J Infect Dis       Date:  2003-05-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.